Trading to commence effective with the open of
business on June 13, 2023
WEXFORD,
Pa. , June 9, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the
"Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced today that it received
approval from the Nasdaq Stock Market of the Company's request to
transfer its listing to the Nasdaq Capital Market from the Nasdaq
Global Select Market. Trading on the Nasdaq Capital Market will
commence effective with the open of business on June 13, 2023, under Coeptis' current ticker
symbols, "COEP" and "COEPW."
The Nasdaq Capital Market operates in
substantially the same manner as The Nasdaq Global Market,
including a requirement that companies listed on The Nasdaq Capital
Market maintain certain financial requirements and corporate
governance standards in order to maintain continued listing.
About Coeptis Therapeutics Holdings,
Inc.
Coeptis Therapeutics Holdings, Inc., together
with its subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and intellectual property and
knowhow related to the GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that currently explored expansion
opportunities, if consummated, disrupts current plans and
operations of Company; (3) the inability to recognize the
anticipated benefits of the recently closed business combination,
which may be affected by, among other things, competition, the
ability of the Company to grow and manage growth economically and
hire and retain key employees; (4) the risks that the Company's
products in development or those targeted to enter the clinical
trial phase fail clinical trials or are not approved by the U.S.
Food and Drug Administration or other applicable regulatory
authorities; (5) costs related to our ongoing asset development
plans and our focus on business expansion opportunities; (6)
changes in applicable laws or regulations; (7) the possibility that
the Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise
these forward-looking statements to reflect events or circumstances
that arise after the date hereof unless required by applicable
laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-receives-approval-to-transfer-to-the-nasdaq-capital-market-301846803.html
SOURCE Coeptis Therapeutics